Dihydromyricetin and Neuroinflammation: Implications for CNS Disorders and Therapeutic Development
- 1Titus Family Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, CA 90033, USA
Abstract
Dihydromyricetin (DHM) is a bioactive polyphenol with broad therapeutic potential, including strong anti-inflammatory activity. Importantly, DHM has been shown to cross the blood–brain barrier (BBB), enabling pharmacological activity within the central nervous system (CNS) and positioning it as a candidate for CNS disorders in which neuroinflammation plays a central role, including Alzheimer’s disease, Parkinson’s disease, and stroke. Therapeutics such as DHM, which address neuroinflammation, are of increasing interest. Across CNS disease models, DHM’s effects show recurring convergence on NF-κB suppression, NLRP3 inflammasome inhibition, and autophagy regulation, alongside context-specific mechanisms involving oxidative stress, ferroptosis, neurotrophic signaling, and peripheral gut–CNS communication. This review examines the evidence for DHM as a neuroinflammatory modulator, focusing on the mechanisms by which it exerts its therapeutic effects. By doing so, we aim to support its translational potential as a natural product for improving human health.
Related
- Photobiomodulation as a regulator of neuroinflammation: mechanistic insights and therapeutic potential in brain disorders
- Microglia in Psychiatric Disorders: Stage-Dependent Roles and Therapeutic Implications
- Tumor heterogeneity: development, mechanisms, and therapeutic implications
- Hallmarks of aging in systemic sclerosis: implications for pathogenesis, multimorbidity, and therapeutic development.
- The obesity–neuroinflammation–cancer axis: neuroimmune remodeling and therapeutic opportunities
BibTeX
@article{skinner2026dihydromyricetin,
title = {{Dihydromyricetin and Neuroinflammation: Implications for CNS Disorders and Therapeutic Development}},
author = {Samantha G. Skinner and Eliana G. Aleman and Ashley N. Berges and Katie J. Kim and Dhruv Kantilal and Liana Asatryan and Daryl L. Davies},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209080},
url = {https://www.mdpi.com/1422-0067/27/20/9080},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dihydromyricetin and Neuroinflammation: Implications for CNS Disorders and Therapeutic Development
AU - Samantha G. Skinner
AU - Eliana G. Aleman
AU - Ashley N. Berges
AU - Katie J. Kim
AU - Dhruv Kantilal
AU - Liana Asatryan
AU - Daryl L. Davies
PY - 2026
DA - 2026/10/13
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209080
UR - https://www.mdpi.com/1422-0067/27/20/9080
AB - Dihydromyricetin (DHM) is a bioactive polyphenol with broad therapeutic potential, including strong anti-inflammatory activity. Importantly, DHM has been shown to cross the blood–brain barrier (BBB), enabling pharmacological activity within the central nervous system (CNS) and positioning it as a candidate for CNS disorders in which neuroinflammation plays a central role, including Alzheimer’s disease, Parkinson’s disease, and stroke. Therapeutics such as DHM, which address neuroinflammation, are of increasing interest. Across CNS disease models, DHM’s effects show recurring convergence on NF-κB suppression, NLRP3 inflammasome inhibition, and autophagy regulation, alongside context-specific mechanisms involving oxidative stress, ferroptosis, neurotrophic signaling, and peripheral gut–CNS communication. This review examines the evidence for DHM as a neuroinflammatory modulator, focusing on the mechanisms by which it exerts its therapeutic effects. By doing so, we aim to support its translational potential as a natural product for improving human health.
SN - 1422-0067
ER -